It’s O’Day day at Gilead

Gilead Sciences’s share price is down about 20% since 2018. Its next-big thing just failed, and it might have spent $12 billion on a niche business that will never turn a profit.

That’s the welcome mat laid out before Daniel O’Day, the newly minted CEO who will today host his first quarterly update to investors.

Whether he’ll stray too far from the banal patois of CEOspeak remains to be seen, but there will be pointed questions. Among them: Why should anyone care about the rest of Gilead’s 2019? What’s going on with that anti-inflammatory drug? And, of course, what are you going to buy?

Read more.